Product Description
Vinblastine, a chemotherapeutic drug, inhibits palmitoylation of tubulin in human leukemic lymphocytes (Sourced from: https://pubmed.ncbi.nlm.nih.gov/17202812/)
Mechanisms of Action: Tubulin Inhibitor,Mitosis Inhibitor,P-gp Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Brazil, Canada, Italy, Japan, New Zealand, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Lymphoma
Phase 2: Glioma|Hodgkin Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2017-002935-40 | P3 |
Active, not recruiting |
Lymphoma |
2028-08-17 |
|
| Vinblastine +/- Bevacizumab for treatment of pediatric LGG | P2 |
Unknown status |
Glioma |
2028-01-26 |
|
| NCT02840409 | P2 |
Active, not recruiting |
Glioma |
2024-07-31 |
|
| C25004 | P2 |
Active, not recruiting |
Hodgkin Lymphoma |
2020-05-05 |